Sep
23
2020
On demand

Optimizing antibody discovery strategy for clinical success of next-gen immuno-oncology therapeutics

Sponsor
Optimizing antibody discovery strategy for clinical success of next-gen immuno-oncology therapeutics

The successful clinical application of antibody-based therapeutics initially triggered the generation of various high-throughput and reliable antibody discovery platforms, each with its own unique advantages.

Today, as the immuno-oncology field strives to develop the next wave of safe, efficacious antibody therapeutics, the question has become: how can we best leverage these tools and approaches to maximize the potential for success in both translational and clinical R&D?

During this webinar, ImmunoPrecise Antibodies (IPA) will present a case study exploring the high-throughput identification of genetically distinct, target-specific antibodies as the driving force behind a streamlined, end-to-end antibody discovery and development pipeline. A multi-stakeholder panel including industry experts and a leading immuno-oncology clinician will then discuss key considerations for novel antibody therapeutic research from the clinical development perspective.

Attendees will discover:

  • How to run a solid and strong antibody discovery campaign in a relatively short timeframe.
  • The direct correlation between the success of a complex antibody discovery campaign, the robustness of the antibody discovery technologies used, and optimized developability analysis.
  • How to overcome tolerance issues, allowing for more reliable preclinical evaluation of lead candidates without reliance on surrogate antibodies.
  • Keys to preparing for translational and clinical success with novel antibody-based therapeutic technologies.
Patrick Ott

Dr Patrick Ott, MD, PhD

Clinical Director of The Center for Immuno-Oncology, Dana Farber Cancer Institute

Dr. Patrick Ott is currently the Clinical Director of both the Melanoma Disease Center and the Center for Immuno-Oncology at DFCI, serves as attending physician in the Department of Medicine at Brigham and Women’s Hospital, and has an appointment as Associate Professor at Harvard Medical School in Boston, MA. Dr. Ott received his MD and PhD from Ludwig Maximilians University of Munich, Germany. He completed post-doctoral training in Immunology and residency training in Medicine at Case Western Reserve University. After a fellowship in Hematology-Oncology and 4 years on the faculty at New York University, he moved to Dana Farber Cancer Institute (DFCI) in 2012.

He is a clinical investigator and an integral member of the clinical trials program at Dana Farber/Harvard Cancer Center, where he designs and conducts phase 1 immunotherapy trials for patients with melanoma and a wide range of other tumors. His primary research interests are in melanoma and immunotherapy, specifically the development of innovative tumor vaccine approaches. Dr. Ott has been the Principal Investigator of a first in man clinical trial testing a personalized neoantigen vaccine (NeoVax) in patients with melanoma. The results of the study, reported in in Nature in 2017, established the feasibility and safety of this novel cancer vaccine approach for the first time in a coordinated clinical trial setting. Strong and consistent immunogenicity was demonstrated in patients with high risk melanoma, providing the basis for further testing of this innovative new treatment concept in other cancers. He has been the Principal Investigator and co-investigator on over 30 treatment trials, including those that have been instrumental in the clinical development of the newly FDA approved drugs pembrolizumab and nivolumab for the treatment of advanced melanoma, small cell lung cancer, and many other cancers. This work has resulted in numerous high impact publications including the New England Journal of Medicine, the Lancet Oncology, and the Journal of Clinical Oncology.

 Dr Ilse Roodink

Dr Ilse Roodink

Scientific Director, ImmunoPrecise Antibodies

Ilse Roodink obtained a PhD in Medical Sciences at the Radboud University of Nijmegen, The Netherlands in 2009 and continued her research as a postdoctoral researcher developing an in vitro platform to isolate single domain antibodies specifically recognizing tumor targets in its native conformation using phage display technology. In 2013, Ilse joined ImmunoPrecise Antibodies (Europe) as a scientist actively involved in phage display-oriented antibody discovery projects. She was promoted to Scientific Director in 2019, where she is responsible for contract research project execution and management. Ilse is also actively involved in integration of innovative technologies supporting antibody characterization and engineering.

Nina Senutovitch, PhD

Nina Senutovitch, PhD

Senior Scientist, Cell Analytics Development, Sartorius

Dr. Nina Senutovitch received her BS in Biochemistry from New Mexico State University. She completed her PhD in Biological Sciences from Carnegie Mellon University, where she developed and detailed the function of novel fluorescent probes. As a post-doctoral fellow at the University of Pittsburgh, she established biosensor-based live cell screening assays for the detection of hepatotoxicity, including the use of a human liver “organ on a chip” model. She joined Sartorius in 2019 as a Senior Scientist in Cell Analytics

SPEAKERS

Patrick Ott
Patrick Ott
Clinical Director at Harvard Medical School
Ilse Roodink
Ilse Roodink
Scientific Director at ImmunoPrecise Antibodies
Nina Senutovitch
Nina Senutovitch
Senior Scientist, Cell Analytics Development at Sartorius

You might also like